{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T12:52:45Z","timestamp":1785156765002,"version":"3.55.0"},"reference-count":31,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T00:00:00Z","timestamp":1571011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100004824","name":"Danish Society of Nephrology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004915","name":"Nyreforeningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020219","name":"Helen and Ejnar Bj\u00f8rnow Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100020219","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>The insulin-stimulating and glucagon-regulating effects of the 2 incretin hormones, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), contribute to maintain normal glucose homeostasis. Impaired glucose tolerance occurs with high prevalence among patients with end-stage renal disease (ESRD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate the effect of the incretin hormones on endocrine pancreatic function in patients with ESRD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design and Setting<\/jats:title>\n                  <jats:p>Twelve ESRD patients on chronic hemodialysis and 12 matched healthy controls, all with normal oral glucose tolerance test, were included. On 3 separate days, a 2-hour euglycemic clamp followed by a 2-hour hyperglycemic clamp (3 mM above fasting level) was performed with concomitant infusion of GLP-1 (1 pmol\/kg\/min), GIP (2 pmol\/kg\/min), or saline administered in a randomized, double-blinded fashion. A 30% lower infusion rate was used in the ESRD group to obtain comparable incretin hormone plasma levels.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>During clamps, comparable plasma glucose and intact incretin hormone concentrations were achieved. The effect of GLP-1 to increase insulin concentrations relative to placebo levels tended to be lower during euglycemia in ESRD and was significantly reduced during hyperglycemia (50 [8\u201372]%, P = 0.03). Similarly, the effect of GIP relative to placebo levels tended to be lower during euglycemia in ESRD and was significantly reduced during hyperglycemia (34 [13\u201350]%, P = 0.005). Glucagon was suppressed in both groups, with controls reaching lower concentrations than ESRD patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The effect of incretin hormones to increase insulin release is reduced in ESRD, which, together with elevated glucagon levels, could contribute to the high prevalence of impaired glucose tolerance among ESRD patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgz048","type":"journal-article","created":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T11:37:41Z","timestamp":1571053061000},"page":"e564-e574","source":"Crossref","is-referenced-by-count":7,"title":["Effect of the Incretin Hormones on the Endocrine Pancreas in End-Stage Renal Disease"],"prefix":"10.1210","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9681-3134","authenticated-orcid":false,"given":"Morten B","family":"J\u00f8rgensen","sequence":"first","affiliation":[{"name":"Department of Nephrology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Idorn","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casper","family":"Rydahl","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Herlev Hospital, University of Copenhagen, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik P","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Herlev Hospital, University of Copenhagen, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"Bressendorff","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Endocrinology and Nephrology, Nordsj\u00e6llands Hospital, University of Copenhagen, Hiller\u00f8d, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisbet","family":"Brandi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Endocrinology and Nephrology, Nordsj\u00e6llands Hospital, University of Copenhagen, Hiller\u00f8d, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolai J","family":"Wewer Albrechtsen","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrit","family":"van Hall","sequence":"additional","affiliation":[{"name":"Clinical Metabolomics Core Facility, Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark"},{"name":"Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8509-2036","authenticated-orcid":false,"given":"Bolette","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens J","family":"Holst","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3845-3465","authenticated-orcid":false,"given":"Filip K","family":"Knop","sequence":"additional","affiliation":[{"name":"The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"Steno Diabetes Center Copenhagen, Gentofte, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Hornum","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Feldt-Rasmussen","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2019,10,14]]},"reference":[{"key":"2021122102221551900_CIT0001","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/S0026-0495(78)80005-5","article-title":"Pathogenesis of glucose intolerance in uremia","volume":"27","author":"DeFronzo","year":"1978","journal-title":"Metabolism."},{"issue":"4","key":"2021122102221551900_CIT0002","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1093\/ndt\/gfp558","article-title":"Pre-diabetes and arterial stiffness in uraemic patients","volume":"25","author":"Hornum","year":"2010","journal-title":"Nephrol Dial Transplant."},{"issue":"4","key":"2021122102221551900_CIT0003","doi-asserted-by":"crossref","first-page":"616","DOI":"10.2215\/CJN.07501009","article-title":"Undiagnosed diabetes in kidney transplant candidates: a case-finding strategy","volume":"5","author":"Bergrem","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"issue":"9179","key":"2021122102221551900_CIT0004","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(98)12131-1","article-title":"Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe","volume":"354","year":"1999","journal-title":"Lancet."},{"issue":"10","key":"2021122102221551900_CIT0005","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.2337\/dc12-2148","article-title":"Epidemiology and mortality of new-onset diabetes after dialysis: Taiwan national cohort study","volume":"36","author":"Tien","year":"2013","journal-title":"Diabetes Care."},{"issue":"5","key":"2021122102221551900_CIT0006","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/ki.2012.460","article-title":"Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease","volume":"83","author":"Idorn","year":"2013","journal-title":"Kidney Int."},{"issue":"2","key":"2021122102221551900_CIT0007","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"Nauck","year":"1986","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2021122102221551900_CIT0008","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1210\/jc.2003-030738","article-title":"The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype","volume":"88","author":"Vilsb\u00f8ll","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2021122102221551900_CIT0009","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2337\/diabetes.52.2.380","article-title":"The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects","volume":"52","author":"Kjems","year":"2003","journal-title":"Diabetes."},{"issue":"12","key":"2021122102221551900_CIT0010","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1210\/jc.2009-0921","article-title":"Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus","volume":"94","author":"Hare","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"2021122102221551900_CIT0011","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabet Med."},{"issue":"7","key":"2021122102221551900_CIT0012","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1210\/jc.2013-3809","article-title":"Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease","volume":"99","author":"Idorn","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2021122102221551900_CIT0013","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1172\/JCI111542","article-title":"Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus","volume":"74","author":"Ward","year":"1984","journal-title":"J Clin Invest."},{"issue":"9","key":"2021122102221551900_CIT0014","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00125-014-3283-z","article-title":"Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?","volume":"57","author":"Wewer Albrechtsen","year":"2014","journal-title":"Diabetologia."},{"key":"2021122102221551900_CIT0015","doi-asserted-by":"crossref","first-page":"8352957","DOI":"10.1155\/2016\/8352957","article-title":"Inability of some commercial assays to measure suppression of glucagon secretion","volume":"2016","author":"Wewer Albrechtsen","year":"2016","journal-title":"J Diabetes Res."},{"issue":"10","key":"2021122102221551900_CIT0016","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/jms.3407","article-title":"Glucose and glycerol concentrations and their tracer enrichment measurements using liquid chromatography tandem mass spectrometry","volume":"49","author":"Born\u00f8","year":"2014","journal-title":"J Mass Spectrom."},{"issue":"1","key":"2021122102221551900_CIT0017","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1530\/EC-14-0126","article-title":"Stability of glucagon-like peptide 1 and glucagon in human plasma","volume":"4","author":"Wewer Albrechtsen","year":"2015","journal-title":"Endocr Connect."},{"issue":"10","key":"2021122102221551900_CIT0018","first-page":"3575","article-title":"Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide","volume":"85","author":"Deacon","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"key":"2021122102221551900_CIT0019","volume-title":"Isotope Tracers in Metabolic Research. Principles and Practice of Kinetic Analysis.","author":"Wolfe","year":"1992","edition":"2nd ed"},{"issue":"2 Pt 1","key":"2021122102221551900_CIT0020","first-page":"E241","article-title":"Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans","volume":"257","author":"Luzi","year":"1989","journal-title":"Am J Physiol."},{"key":"2021122102221551900_CIT0021","article-title":"Data from: Effect of the incretin hormones on the endocrine pancreas in end-stage renal disease","author":"J\u00f8rgensen","journal-title":"Mendeley Data, V3. Deposited 20 August 2019"},{"issue":"10","key":"2021122102221551900_CIT0022","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/0026-0495(85)90148-9","article-title":"Glucose metabolism and insulin sensitivity in patients on chronic hemodialysis","volume":"34","author":"Graf","year":"1985","journal-title":"Metabolism."},{"issue":"2","key":"2021122102221551900_CIT0023","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1530\/acta.0.1210251","article-title":"Effects of physiologic and supraphysiologic hyperglycemia on early and late-phase insulin secretion in chronically dialyzed uremic patients","volume":"121","author":"Schmitz","year":"1989","journal-title":"Acta Endocrinol (Copenh)."},{"issue":"2","key":"2021122102221551900_CIT0024","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1172\/JCI109144","article-title":"Glucose intolerance in uremia. Quantification of pancreatic beta cell sensitivity to glucose and tissue sensitivity to insulin","volume":"62","author":"DeFronzo","year":"1978","journal-title":"J Clin Invest."},{"key":"2021122102221551900_CIT0025","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.2337\/diabetes.51.2007.S265","article-title":"Disturbances in beta-cell function in impaired fasting glycemia","volume":"51","author":"van Haeften","year":"2002","journal-title":"Diabetes."},{"issue":"8","key":"2021122102221551900_CIT0026","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.2337\/dc06-0438","article-title":"Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans","volume":"29","author":"Meyer","year":"2006","journal-title":"Diabetes Care."},{"issue":"2","key":"2021122102221551900_CIT0027","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2337\/db11-0995","article-title":"Distinct \u03b2-cell defects in impaired fasting glucose and impaired glucose tolerance","volume":"61","author":"Kanat","year":"2012","journal-title":"Diabetes."},{"issue":"7","key":"2021122102221551900_CIT0028","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.2337\/db14-1751","article-title":"GLP-1 response to oral glucose is reduced in prediabetes, screen-detected type 2 diabetes, and obesity and influenced by sex: the ADDITION-PRO study","volume":"64","author":"F\u00e6rch","year":"2015","journal-title":"Diabetes."},{"issue":"4","key":"2021122102221551900_CIT0029","first-page":"175","article-title":"Glucose intolerance in uremic patients: the relative contributions of impaired beta-cell function and insulin resistance","volume":"31","author":"Alvestrand","year":"1989","journal-title":"Clin Nephrol."},{"issue":"3","key":"2021122102221551900_CIT0030","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/tri.12907","article-title":"The impact of kidney transplantation on insulin sensitivity","volume":"30","author":"J\u00f8rgensen","year":"2017","journal-title":"Transpl Int."},{"issue":"1","key":"2021122102221551900_CIT0031","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/ki.1990.174","article-title":"Plasma and muscle free amino acids in maintenance hemodialysis patients without protein malnutrition","volume":"38","author":"Bergstr\u00f6m","year":"1990","journal-title":"Kidney Int."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgz048\/30143386\/dgz048.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/3\/e564\/41823334\/jcem_105_3_e564.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/3\/e564\/41823334\/jcem_105_3_e564.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T02:23:51Z","timestamp":1640053431000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/105\/3\/e564\/5586894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,14]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,10,14]]},"published-print":{"date-parts":[[2020,3,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgz048","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3]]},"published":{"date-parts":[[2019,10,14]]}}}